综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Policies

Healthcare on the cusp of big leap

By LIU ZHIHUA | China Daily | Updated: 2020-12-07 07:39
Share
Share - WeChat
Staff members inspect equipment at a production workshop of Novo Nordisk (China) Pharmaceuticals on Feb 25. The parent company will invest $30.5 million to set up a new unit at the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone. [Photo/Xinhua]

China's economic resilience, policy supports, long-term strategy attract big-ticket investments

Tailwinds are not only offsetting the negative economic impact of COVID-19 on China's healthcare industry but also speeding up its evolution, heralding restructuring, expansion and rise in foreign investment flows, industry insiders said.

The glad tidings promise to make health one of society's top priorities as the nation swears by the new dual-circulation pattern for high-quality development in the post-pandemic era.

A confluence of several factors-growing demand for higher-quality healthcare, improved protection for intellectual property rights, deepening of China's reform and opening-up, reinforced commitment to globalization, a business-friendly environment, integration of cutting-edge technologies into the medical field, new agreements for regional trade and economic cooperation, and a long-term national health strategy-h(huán)as created a near-perfect setting for the next big leap of the healthcare industry, they said.

To be sure, COVID-19 has caused massive job losses and a sharp fall in global foreign direct investment flows, but a quicker-than-expected economic recovery and remarkable resilience have made China one of the most attractive investment destinations in the global healthcare industry.

For instance, during the third China International Import Expo in early November in Shanghai, Novo Nordisk, a global healthcare leader in diabetes treatment, announced it will invest 200 million yuan ($30.5 million) to establish a new facility at the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone.

Novo Nordisk's new unit will foray into several market segments, including marketing, pharmaceutical research and development, and finished goods imports and distribution.

"The excellent business environment and preferential policy support in the Lingang Special Area will allow this new entity to become a powerful driver of Novo Nordisk's strategy of solidifying its value chain in China," the company said in a statement.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
迁安市| 中江县| 文成县| 长武县| 镇远县| 商南县| 济南市| 泾源县| 岳池县| 宁蒗| 台安县| 襄樊市| 阳江市| 天气| 疏附县| 宁波市| 莆田市| 盐城市| 六枝特区| 高雄市| 视频| 石狮市| 琼海市| 五莲县| 志丹县| 卫辉市| 镇安县| 花莲市| 霍州市| 甘肃省| 东丽区| 手机| 高尔夫| 昭苏县| 漯河市| 正镶白旗| 错那县| 图片| 满城县| 虞城县| 利津县|